GSK Enters Agreement with U.S. Government to Lower Drug Prices

GSK plc has entered into an agreement with the U.S. Administration to reduce the cost of prescription medicines for American patients. This agreement specifically addresses GSK's respiratory portfolio, which is used by over 40 million Americans suffering from conditions like asthma and COPD. The agreement fulfills all four requests made by President Trump in July, leading to lower prices for certain Medicaid drugs and the introduction of new products with a balanced pricing strategy. GSK will also offer a significant portion of its inhaled respiratory products through a direct purchasing platform, potentially providing savings of up to 66%. Additionally, GSK will establish a reserve of albuterol for the U.S. as part of the President's Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), enhancing the U.S. supply chain for critical medicines. These agreements, which include ViiV Healthcare, provide pricing framework clarity and exclude both companies from s232 tariffs for three years. GSK CEO Emma Walmsley emphasized the company's commitment to increasing access and affordability of medicines globally, building on decades of respiratory innovation.